- Home
- WAL vs ROIV Comparison
WAL vs ROIV Comparison
Compare WAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WAL | ROIV |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 14.1B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | WAL | ROIV |
|---|---|---|
| Price | $87.52 | $22.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $99.64 | $24.31 |
| AVG Volume (30 Days) | 923.0K | ★ 8.2M |
| Earning Date | 01-26-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 24.99 | N/A |
| EPS | ★ 8.09 | N/A |
| Revenue | ★ $3,189,400,000.00 | $20,329,000.00 |
| Revenue This Year | $16.21 | N/A |
| Revenue Next Year | $9.07 | $376.94 |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | ★ 9.57 | N/A |
| 52 Week Low | $57.05 | $8.73 |
| 52 Week High | $94.40 | $23.47 |
Technical Indicators
Market Signals| Indicator | WAL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 61.92 |
| Support Level | $85.14 | $21.60 |
| Resistance Level | $87.78 | $23.47 |
| Average True Range (ATR) | 2.27 | 0.88 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 74.34 | 68.97 |
Price Performance
Historical ComparisonAbout WAL Western Alliance Bancorporation (DE)
Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.